ARCHIVES

Unwanted Distinction: MSKCC Bars Zaltrap From Formulary, Triggering Debate Over Drug Pricing

This article is from The Cancer Letter archive.

Vol. 38 No. 41 | November 1, 2012

Download PDF Visit The Full Archive

Related Articles

New Approaches To Improve Diagnoses In Urogenital Cancers Presented At AUA

September 24, 2004

ACCC Presses Drive for “DG 471” But Former President Says it’s Counterproductive

March 30, 1984

Neulasta Reduces Incidence Of Febrile Neutropenia

February 22, 2013

Tamoxifin Benefits Outweigh Risks, NSABP Study Finds

March 23, 1994

Tobacco Company Liggett Gave $3.6 Million To Henschke For CT Screening Research.

March 28, 2008

Study Validates “PEM” Scans As Biopsy Guidance Method

April 29, 2011